EUVIMEDEUVIMED entdecken
Crossref

3-(Bromoacetyl) coumarin is a potential therapeutic agent against neonatal sepsis-associated Pseudomonas extremorientalis

Shukla Banerjee, Sukesh Kumar Bajire, H K Mithun, Rajesh P Shastry

Archives of Microbiology · 2023

DOI: 10.1007/s00203-023-03653-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Microbiology, 2023. Verfasst von Shukla Banerjee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Microbiology and Biotechnology, Yenepoya Research Centre, Yenepoya (Deemed to be University), University Road, Deralakatte, Mangaluru, 57…. Hauptthemen laut MEDLINE: Neonatal Sepsis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: DST-SYST, New Delhi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neonatal sepsis is a severe bacterial infection that can lead to life-threatening complications in newborns. Pseudomonas extremorientalis is a Gram-negative bacterium and these Gram-negative organisms have been identified as a major cause of neonatal sepsis. The virulence factors produced by this bacterium play a crucial role in its pathogenicity. Therefore, targeting these virulence factors could be a potential strategy to treat neonatal sepsis caused by P. extremorientalis. In this study, we investigated the efficacy of 3-(bromoacetyl) coumarin (3-BC) in reducing the virulence factors of P. extremorientalis strains isolated from neonatal sepsis. Our results showed that 3-BC effectively reduced the production of various virulence factors, including protease, elastase, siderophore, and exopolysaccharide in these strains. Furthermore, at a concentration of 125 µg/ml, 3-BC also inhibited the biofilm formation ability of these strains in combination with ciprofloxacin. It was discovered that 3-BC was functionally effective in protecting C. elegans against bacterial infection. Moreover, the in vitro and in vivo outcomes were strongly correlated with docking studies of various activator proteins. Overall, our findings suggest that 3-BC could be a potential therapeutic agent for the treatment of neonatal sepsis caused by P. extremorientalis. Further studies are needed to explore the mechanism of action of 3-BC and its potential use in clinical settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neonatal SepsisCaenorhabditis elegansPseudomonasInfant, NewbornSerine EndopeptidasesHumansCoumarinsVirulence FactorsAnimals

Stichwörter der Autor:innen

BiofilmCoumarin derivativeNeonatal sepsisPseudomonas extremorientalisVirulence

Substanzen

CoumarinsSerine EndopeptidasesVirulence Factors

Autor:innen und Institutionen

  • Division of Microbiology and Biotechnology, Yenepoya Research Centre, Yenepoya (Deemed to be University), University Road, Deralakatte, Mangaluru, 575018, India.
  • Department of Pediatrics, Yenepoya Medical College Hospital, Yenepoya (Deemed to be University), Deralakatte, Mangaluru, 575018, India.
  • Division of Microbiology and Biotechnology, Yenepoya Research Centre, Yenepoya (Deemed to be University), University Road, Deralakatte, Mangaluru, 575018, India. rpshastry@yenepoya.edu.in.

Förderung

  • DST-SYST, New Delhi

Zitieren

APA

Banerjee, S., Bajire, S. K., Mithun, H. K., & Shastry, R. P. (2023). 3-(Bromoacetyl) coumarin is a potential therapeutic agent against neonatal sepsis-associated Pseudomonas extremorientalis. Archives of Microbiology. https://doi.org/10.1007/s00203-023-03653-2

Vancouver

Banerjee S, Bajire SK, Mithun HK, Shastry RP. 3-(Bromoacetyl) coumarin is a potential therapeutic agent against neonatal sepsis-associated Pseudomonas extremorientalis. Archives of Microbiology. 2023. doi:10.1007/s00203-023-03653-2

BibTeX
@article{Banerjee2023,
  author = {Banerjee, Shukla and Bajire, Sukesh Kumar and Mithun, H K and Shastry, Rajesh P},
  title = {3-(Bromoacetyl) coumarin is a potential therapeutic agent against neonatal sepsis-associated Pseudomonas extremorientalis},
  journal = {Archives of Microbiology},
  year = {2023},
  doi = {10.1007/s00203-023-03653-2}
}
Kostenlos starten →